A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Musisz mieć potwierdzenie obecności białka FAP w guzie.
- •Musisz mieć zdiagnozowanego raka trzustki.
- •Musisz mieć zdiagnozowanego raka piersi (hormonozależnego lub HER2-dodatniego lub potrójnie ujemnego).
- •Musisz mieć zdiagnozowanego raka jajnika opornego na platynę lub nie reagującego na leczenie.
- •Musisz mieć zdiagnozowanego innego raka litego, np. żołądka, jelita grubego, przełyku lub dróg żółciowych.
- •W zależności od rodzaju raka, musiałeś już przejść określone wcześniejsze leczenie.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
Hoag Memorial Hospital Presbyterian
Newport Beach, United States
Stanford University Medical Center
Stanford, United States
Biogenix Molecular, LLC
Miami, United States
Moffitt
Tampa, United States
Indiana University (IU) School of Medicine
Indianapolis, United States
United Theranostics
Glen Burnie, United States
Massachusetts General Hospital
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
BAMF Health Inc.
Grand Rapids, United States
Mayo Clinic - Rochester
Rochester, United States
Washington University School of Medicine in St. Louis
St Louis, United States
New York University (NYU) Clinical Cancer Center
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Duke University Medical Center
Durham, United States
University of Pennsylvania
Philadelphia, United States
Fox Chase Cancer Center
Philadelphia, United States
Texas Oncology - DFW (Sammons CC)
Dallas, United States
Baylor College of Medicine
Houston, United States
University of Wisconsin - Carbone Cancer Center
Madison, United States
Fudan University Zhongshan Hospital
Shanghai, China
Universitaetsklinikum Essen
Essen, Germany
National Cancer Center Hospital East
Chiba, Japan
Kyoto University Hospital
Kyoto, Japan
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
Amsterdam, Netherlands
Amsterdam UMC - Locatie VUmc
Amsterdam, Netherlands
Erasmus MC
GE Rotterdam, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Stichting Radboud Universitair Medisch Centrum
Nijmegen, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.